Acquisitions and big partnerships have these small co's rockin 🎸

October 28, 2024 | [Read Online]( In partnership with Good day, 360! Jason Bond is on a HOT STREAK! Trading is hard and results should not be expected to be replicated but Jason Bond can teach you [the strategies that helped him return over 1900%]( recently. His SPOOKTACULAR special ends Thursday so get yourself in there now! [Spooktacular]( 👻I [Oktoberfest]( 🍺 FOCUS LIST🔎 HCTI - Up over 140% in the pre-market after the company disclosed in a filing that it acquired the business, assets, and operations relating to cloud and technology domain of Securekloud Technologies. EVOK - Up over 100% in pre after announcing statistically significant improvement in patient outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI® GLUE - Up over 30% in pre after announcing global license agreement with Novartis to advance T and B cell-modulating VAV1-directed Molecular Glue Degraders *Sponsored by Vinovest Whiskey: A Hedge Against Market Volatility Looking to protect your portfolio from the next recession? Consider investing in rare spirits like whiskey. Whiskey investing provides a proven hedge against stock market dips driven by inflation and other factors. With [Vinovest](, you can invest in high-growth segments such as American Single Malt, emerging Scotch, Bourbon, and Irish whiskey. Thanks to established industry relationships, Vinovest overcomes industry barriers that have made historically whiskey investing expensive and opaque. As a result, you can enjoy high-quality inventory that boosts your portfolio value and enhances liquidity. [Schedule a call with a Vinovest advisor to learn more.]( HOTLIST🔥 HCTI - Up over 140% in the pre-market after the company disclosed in a filing that it acquired the business, assets, and operations relating to cloud and technology domain of Securekloud Technologies. Healthcare Triangle Inc. (HCTI) is a healthcare information technology company that focuses on developing solutions in the sectors of cloud services, data science, and professional and managed services for the electronic health record, and healthcare and life sciences industry. In the pre-market this morning, the company [disclosed in a filing]( that it acquired the business, assets, and operations relating to cloud and technology domain of Securekloud Technologies. SecureKloud is an industry-recognized global leader in the Cloud services arena. Shares of HCTI traded up over 100% in the premarket in reaction to the news. The $1.14 area acted as resistance in the after-hours and then support in the pre-market. Above it, targets to the upside are $1.25, $1.40 and then the pre-market high at $1.43. Beyond that, $1.80, $2.25 and $2.90 come into play. Below $1.14, targets to the downside are $1, $0.80, $0.70 and then a gap fill at $0.58. EVOK - Up over 200% in pre after announcing statistically significant improvement in patient outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI® Evoke Pharma Inc. (EVOK) is a specialty pharmaceutical company that primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. In the pre-market this morning, the company, together with EVERSANA, a leading provider of global commercial services to the life sciences industry, [announced the presentation]( of data for GLP-1 users with diabetic gastroparesis using GIMOTI at the American College of Gastroenterology (ACG) 2024 Annual Meeting. Highlights include: Analysis of real-world data compared patients on GIMOTI (n=51) to Oral Metoclopramide (n=41), both taking GLP-1s, showing significant statistical improvement for GIMOTI over Oral Metoclopramide in All Cause Emergency Department Visits (-91%, p=0.001), All Cause Office Visits (-41%, p=0.027) and All Cause Hospital Outpatient Visits (-89%, p=0.032) within 6-month index period Data presented at American College of Gastroenterology (ACG) 2024; the submission garnered both the Presidential Poster Award as one of the top 5% of data accepted to the conference and selected as the Outstanding Research Award in the Stomach Category First study to show Gimoti’s potential as supportive care for GLP-1 therapy Shares of EVOK traded up over 200% in the pre-market in reaction to the news. The $11.50 area acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $13.30, $14, $15 and then the pre-market high at $17.20. Below $11.50, targets to the downside are $10, $9, $8, $7 $6 and then a gap fill at $5.30. 🔥The Hot Streak Continues 🔥 40 Make that 45 straight wins for the $2,000 Small Account Journey *Balance Update: $2k to $40,511 or +1,926% Jason Bond will teach you – up for the challenge?! [50% OFF ENDS OCT 31st!]( *Trading is hard, results not guaranteed and should not be expected to be replicated typically. GLUE - Up over 30% in pre after announcing global license agreement with Novartis to advance T and B cell-modulating VAV1-directed Molecular Glue Degraders Monte Rosa Therapeutics, Inc. (GLUE) is a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines. In the pre-market this morning, the [company announced]( a global exclusive development and commercialization license agreement with Novartis to advance VAV1 MGDs, including MRT-6160. The agreement is expected to accelerate MRT-6160 clinical development and broadly explore therapeutic opportunities across multiple indications Monte Rosa to receive up-front payment of $150 million and is eligible to receive milestone payments, U.S. profit and loss share, and tiered royalties on ex-U.S. net sales Monte Rosa is eligible to receive up to $2.1 billion in development, regulatory, and sales milestones, beginning upon initiation of Phase 2 studies, as well as tiered royalties on ex-U.S. net sales. Monte Rosa will co-fund any Phase 3 clinical development and will share any profits and losses associated with the manufacturing and commercialization of MRT-6160 in the U.S. Shares of GLUE traded up over 30% in the pre-market in reaction to the news. The $6.20 area acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $6.60, $7, $7.50 and then the pre-market high at $7.71. Beyond that, targets to the upside are $8.20 and $8.70. Below $6.20, targets to the downside are $6.10, $6, $5.50, $5 and then a gap fill at $4.89. MARKET NEWS 📰 P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. *Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 2024 360 WallStreet 62 Calef Hwy. #233 lee, NH 03861, United States of America [Terms of Service](